Begin main content

Kyprolis for Multiple Myeloma (relapsed) – Details

Project Number pCODR 10084
Brand Name Kyprolis
Generic Name Carfilzomib
Strength 60 mg per vial
Tumour Type Lymphoma and Myeloma
Indication Multiple Myeloma (relapsed)
Funding Request In combination with dexamethasone alone in the treatment of patients with relapsed multiple myeloma who have received 1 to 3 prior lines of therapy
Review Status Under Review
Pre Noc Submission Yes
NOC Date November 22, 2016
Manufacturer Amgen Canada Inc.
Submitter Amgen Canada Inc.
Submission Date September 9, 2016
Submission Deemed Complete September 16, 2016
Submission Type New Indication
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ September 23, 2016
Check-point meeting November 1, 2016
pERC Meeting January 19, 2017
Initial Recommendation Issued February 2, 2017
Feedback Deadline ‡ February 16, 2017
pERC Reconsideration Meeting March 16, 2017
Final Recommendation Issued (target date) March 30, 2017
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.